Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient

Scott F. Lindsey, Jonathan Weiss, Eric S. Lee, Paolo Romanelli

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Psoriasis in HIV-infected patients poses a distinct challenge to the dermatologist due to its increased severity, tendency to be refractory to common treatment modalities, and necessity for cautious use of immunosuppressive agents. Tumor necrosis factor-α inhibitors have been shown to be safe and effective for the treatment of psoriasis in the general population, but their role in the treatment of HIV-positive patients is still unclear. The use of the tumor necrosis factor-α inhibitor adalimumab for the treatment of psoriasis in HIV-positive patients has yet to be reported. We present the case of a 49-year-old HIV-positive man with severe plaque psoriasis who has been successfully treated with adalimumab for the past 30 months with no adverse events related to treatment.

Original languageEnglish
Pages (from-to)869-871
Number of pages3
JournalJournal of Drugs in Dermatology
Volume13
Issue number7
StatePublished - Jan 1 2014

Fingerprint

Psoriatic Arthritis
Psoriasis
HIV
Tumor Necrosis Factor-alpha
Therapeutics
Immunosuppressive Agents
Adalimumab
Population

ASJC Scopus subject areas

  • Dermatology

Cite this

Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient. / Lindsey, Scott F.; Weiss, Jonathan; Lee, Eric S.; Romanelli, Paolo.

In: Journal of Drugs in Dermatology, Vol. 13, No. 7, 01.01.2014, p. 869-871.

Research output: Contribution to journalArticle

@article{07d04bf500024a0b816330cf0ce46f29,
title = "Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient",
abstract = "Psoriasis in HIV-infected patients poses a distinct challenge to the dermatologist due to its increased severity, tendency to be refractory to common treatment modalities, and necessity for cautious use of immunosuppressive agents. Tumor necrosis factor-α inhibitors have been shown to be safe and effective for the treatment of psoriasis in the general population, but their role in the treatment of HIV-positive patients is still unclear. The use of the tumor necrosis factor-α inhibitor adalimumab for the treatment of psoriasis in HIV-positive patients has yet to be reported. We present the case of a 49-year-old HIV-positive man with severe plaque psoriasis who has been successfully treated with adalimumab for the past 30 months with no adverse events related to treatment.",
author = "Lindsey, {Scott F.} and Jonathan Weiss and Lee, {Eric S.} and Paolo Romanelli",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "13",
pages = "869--871",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "7",

}

TY - JOUR

T1 - Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient

AU - Lindsey, Scott F.

AU - Weiss, Jonathan

AU - Lee, Eric S.

AU - Romanelli, Paolo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Psoriasis in HIV-infected patients poses a distinct challenge to the dermatologist due to its increased severity, tendency to be refractory to common treatment modalities, and necessity for cautious use of immunosuppressive agents. Tumor necrosis factor-α inhibitors have been shown to be safe and effective for the treatment of psoriasis in the general population, but their role in the treatment of HIV-positive patients is still unclear. The use of the tumor necrosis factor-α inhibitor adalimumab for the treatment of psoriasis in HIV-positive patients has yet to be reported. We present the case of a 49-year-old HIV-positive man with severe plaque psoriasis who has been successfully treated with adalimumab for the past 30 months with no adverse events related to treatment.

AB - Psoriasis in HIV-infected patients poses a distinct challenge to the dermatologist due to its increased severity, tendency to be refractory to common treatment modalities, and necessity for cautious use of immunosuppressive agents. Tumor necrosis factor-α inhibitors have been shown to be safe and effective for the treatment of psoriasis in the general population, but their role in the treatment of HIV-positive patients is still unclear. The use of the tumor necrosis factor-α inhibitor adalimumab for the treatment of psoriasis in HIV-positive patients has yet to be reported. We present the case of a 49-year-old HIV-positive man with severe plaque psoriasis who has been successfully treated with adalimumab for the past 30 months with no adverse events related to treatment.

UR - http://www.scopus.com/inward/record.url?scp=84904119764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904119764&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 869

EP - 871

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 7

ER -